8AK Stock Overview
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Alkermes plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.60 |
| 52 Week High | US$30.20 |
| 52 Week Low | US$21.20 |
| Beta | 0.55 |
| 1 Month Change | -8.87% |
| 3 Month Change | -11.72% |
| 1 Year Change | -14.39% |
| 3 Year Change | n/a |
| 5 Year Change | -15.04% |
| Change since IPO | 111.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8AK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -3.1% | 1.8% |
| 1Y | -14.4% | -22.4% | 2.2% |
Return vs Industry: 8AK exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 8AK underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 8AK volatility | |
|---|---|
| 8AK Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8AK's share price has been volatile over the past 3 months.
Volatility Over Time: 8AK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 2,100 | Richard Pops | www.alkermes.com |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
Alkermes plc Fundamentals Summary
| 8AK fundamental statistics | |
|---|---|
| Market cap | €3.84b |
| Earnings (TTM) | €485.10m |
| Revenue (TTM) | €1.55b |
8.0x
P/E Ratio2.5x
P/S RatioIs 8AK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8AK income statement (TTM) | |
|---|---|
| Revenue | US$1.66b |
| Cost of Revenue | US$253.04m |
| Gross Profit | US$1.41b |
| Other Expenses | US$891.21m |
| Earnings | US$519.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 3.07 |
| Gross Margin | 84.79% |
| Net Profit Margin | 31.21% |
| Debt/Equity Ratio | 24.2% |
How did 8AK perform over the long term?
See historical performance and comparison